articleJAMAMar 3, 2020HYBRID OA

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

London School of Economics and Political Science · London School of Hygiene & Tropical Medicine · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Importance

The mean cost of developing a new drug has been the subject of debate, with recent estimates ranging from $314 million to $2.8 billion.

Objective

To estimate the research and development investment required to bring a new therapeutic agent to market, using publicly available data. DESIGN AND SETTING: Data were analyzed on new therapeutic agents approved by the US Food and Drug Administration (FDA) between 2009 and 2018 to estimate the research and development expenditure required to bring a new medicine to market. Data were accessed from the US Securities and Exchange Commission, Drugs@FDA database, and ClinicalTrials.gov, alongside published data on clinical trial success rates. EXPOSURES: Conduct of preclinical and clinical studies of new therapeutic agents. MAIN OUTCOMES AND MEASURES: Median and mean research and development spending on new therapeutic agents approved by the FDA, capitalized at a real cost of capital rate (the required rate of return for an investor) of 10.5% per year, with bootstrapped CIs. All amounts were reported in 2018 US dollars.

Citation impact

1,473
total citations
FWCI
257.81
Percentile
100%
References
28
Citations per year

Authors

3

Topics & keywords

Keywords
  • Medicine
  • Investment (military)
  • Clinical trial
  • Drug development
  • Clinical research
  • Actuarial science
  • Drug
  • Pharmacology
UN Sustainable Development Goals
  • Partnerships for the goals
No related works found for this paper.